Stoke Therapeutics (NASDAQ:STOK) Receives "Buy" Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK - Free Report) in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a $35.00 price target on the stock.

Several other equities analysts have also recently issued reports on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Leerink Partners started coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an "outperform" rating and a $18.00 price objective on the stock. Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. Chardan Capital began coverage on shares of Stoke Therapeutics in a research note on Friday, December 20th. They issued a "buy" rating and a $24.00 price target for the company. Finally, Leerink Partnrs upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Friday, October 11th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $21.29.

Stoke Therapeutics Stock Down 3.8 %

Shares of NASDAQ STOK traded down $0.35 on Wednesday, reaching $8.96. 1,037,383 shares of the company's stock traded hands, compared to its average volume of 991,057. The business's 50 day simple moving average is $12.05 and its two-hundred day simple moving average is $13.11. Stoke Therapeutics has a 12 month low of $4.09 and a 12 month high of $17.58. The company has a market cap of $474.58 million, a price-to-earnings ratio of -4.27 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $4.89 million during the quarter, compared to analysts' expectations of $3.46 million. Analysts forecast that Stoke Therapeutics will post -2.03 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the transaction, the insider now directly owns 51,277 shares in the company, valued at approximately $618,913.39. The trade was a 16.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Edward M. Md Kaye sold 6,170 shares of the business's stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the sale, the chief executive officer now directly owns 68,671 shares of the company's stock, valued at $877,615.38. This represents a 8.24 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in STOK. Bank of New York Mellon Corp boosted its position in shares of Stoke Therapeutics by 28.9% in the second quarter. Bank of New York Mellon Corp now owns 115,892 shares of the company's stock worth $1,566,000 after purchasing an additional 25,988 shares during the period. Rhumbline Advisers boosted its holdings in Stoke Therapeutics by 14.3% in the 2nd quarter. Rhumbline Advisers now owns 47,860 shares of the company's stock worth $647,000 after buying an additional 5,990 shares during the period. Los Angeles Capital Management LLC increased its stake in Stoke Therapeutics by 7.2% in the 2nd quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company's stock worth $902,000 after buying an additional 4,508 shares in the last quarter. Quest Partners LLC bought a new stake in Stoke Therapeutics during the second quarter valued at about $29,000. Finally, American Century Companies Inc. lifted its position in shares of Stoke Therapeutics by 99.4% in the second quarter. American Century Companies Inc. now owns 59,149 shares of the company's stock valued at $799,000 after acquiring an additional 29,489 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.